The Travelers Companies Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? The Travelers Companies Inc. Common Stock trades at $377.77 (market cap $77.86B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: The Travelers Companies Inc. Common Stock is far larger — about 43.3× Vir Biotechnology Inc. Common Stock's market cap, and The Travelers Companies Inc. Common Stock pays a 1.34% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Travelers Companies Inc. Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| TRV | VIR | |
|---|---|---|
Market Cap | $77.86B | $1.80B |
Volume | 986,776 | 1,782,836 |
Sector | Financials | Health |
52-Week High | $397.22 | $11.78 |
52-Week Low | $261.57 | $5.12 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $86.44B | $1.36B |
Dividend Yield | 1.34% | — |
Signals from Pluang's Aura AI — not financial advice
TRV trades at $373.28, up 0.43% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.03 and ROE of 26.32%, while consistently beating earnings estimates in recent quarters. Recent news highlights Travelers' earnings momentum ahead of Q3 results.
The outlook remains positive given valuation attractiveness and earnings beat history, though risks include competitive pressures and potential earnings volatility. Analyst consensus is mixed with 25% buy ratings but a $353.80 price target below current levels, suggesting cautious optimism.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The Travelers Companies provides property and casualty insurance for individuals, businesses, and organizations. Its products include auto, home, and commercial coverage.
Read more on TRV →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →